Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
Antiepileptic Drugs: GABAergic Pathway Potentiators01:18

Antiepileptic Drugs: GABAergic Pathway Potentiators

γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for their...
Antiepileptic Drugs: Glutamate Antagonists01:14

Antiepileptic Drugs: Glutamate Antagonists

Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
Antiepileptic Drugs: Sodium Channel Blockers01:08

Antiepileptic Drugs: Sodium Channel Blockers

Antiepileptic drugs are specialized medications that prevent seizures in individuals diagnosed with epilepsy. These drugs primarily function by blocking the movement of sodium ions through channels in the neuronal membrane, inhibiting the repetitive firing of action potentials often associated with seizures.
Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
Among the most commonly prescribed antiepileptic drugs are...
Antiepileptic Drugs: Calcium Channel Blockers01:17

Antiepileptic Drugs: Calcium Channel Blockers

Calcium channel blockers, a class of antiepileptic drugs, regulate the flow of calcium ions within neurons.
Calcium channel blockers exert their antiepileptic effects by targeting T-type calcium channels, which are integral to transmitting nerve signals in the central nervous system. These channels allow the passage of calcium ions, which are vital for neuronal communication. By inhibiting T-type calcium channels, calcium channel blockers effectively reduce the release of neurotransmitters and...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Magnetoencephalographic source imaging improves localization of the epileptogenic zone in multimodal imaging evaluation.

Epilepsia·2026
Same author

The TeleEPI Feasibility Study.

Studies in health technology and informatics·2026
Same author

Mood and Age Predict Cognitive Complaints in Memory Clinic Patients: A Machine-Learning and Linear Modeling Approach.

European journal of neurology·2026
Same author

Deep brain stimulation of the thalamus for intractable epilepsy (FRANCE study): A randomized clinical trial.

Epilepsia·2026
Same author

Epilepsy advances in 2025.

Current opinion in neurology·2026
Same author

SUDEP update 2026: recent advances in experimental and clinical research.

Current opinion in neurology·2026

Related Experiment Video

Updated: May 22, 2026

Generation of Local CA1 γ Oscillations by Tetanic Stimulation
08:02

Generation of Local CA1 γ Oscillations by Tetanic Stimulation

Published on: August 14, 2015

Retigabine for partial onset seizures.

Sylvain Rheims1, Philippe Ryvlin

  • 1Department of Functional Neurology & Epileptology and Institute for Children and Adolescent with Epilepsy, Hospices Civils de Lyon, Lyon, France. sylvain.rheims@chu-lyon.fr

Expert Review of Neurotherapeutics
|May 4, 2012
PubMed
Summary
This summary is machine-generated.

Ezogabine (RTG) effectively reduces partial-onset seizures in adults when used as an add-on therapy. This novel antiepileptic drug activates potassium currents to decrease neuronal excitability, showing significant results in clinical trials.

More Related Videos

Electrophoretic Delivery of γ-aminobutyric Acid (GABA) into Epileptic Focus Prevents Seizures in Mice
07:01

Electrophoretic Delivery of γ-aminobutyric Acid (GABA) into Epileptic Focus Prevents Seizures in Mice

Published on: May 16, 2019

Non-restraining EEG Radiotelemetry: Epidural and Deep Intracerebral Stereotaxic EEG Electrode Placement
06:58

Non-restraining EEG Radiotelemetry: Epidural and Deep Intracerebral Stereotaxic EEG Electrode Placement

Published on: June 25, 2016

Related Experiment Videos

Last Updated: May 22, 2026

Generation of Local CA1 γ Oscillations by Tetanic Stimulation
08:02

Generation of Local CA1 γ Oscillations by Tetanic Stimulation

Published on: August 14, 2015

Electrophoretic Delivery of γ-aminobutyric Acid (GABA) into Epileptic Focus Prevents Seizures in Mice
07:01

Electrophoretic Delivery of γ-aminobutyric Acid (GABA) into Epileptic Focus Prevents Seizures in Mice

Published on: May 16, 2019

Non-restraining EEG Radiotelemetry: Epidural and Deep Intracerebral Stereotaxic EEG Electrode Placement
06:58

Non-restraining EEG Radiotelemetry: Epidural and Deep Intracerebral Stereotaxic EEG Electrode Placement

Published on: June 25, 2016

Area of Science:

  • Neuroscience
  • Pharmacology

Background:

  • Epilepsy is a neurological disorder characterized by recurrent seizures.
  • Drug-resistant epilepsy often requires adjunctive therapeutic strategies.
  • Novel antiepileptic compounds are needed to improve treatment outcomes.

Purpose of the Study:

  • To evaluate the efficacy and safety of ezogabine/retigabine (RTG) as adjunctive therapy for adult drug-resistant partial epilepsy.
  • To assess the impact of RTG on seizure frequency and responder rates.

Main Methods:

  • Three pivotal placebo-controlled randomized trials were conducted.
  • Adult patients with drug-resistant partial epilepsy received adjunctive RTG at various dosages (600, 900, 1200 mg/day) or placebo.
  • Seizure frequency and responder rates were primary endpoints.

Main Results:

  • Adjunctive RTG significantly reduced seizure frequency compared to placebo across all tested dosages.
  • Relative risk of responder rate for RTG was 1.71, 2.18, and 2.35 for 600, 900, and 1200 mg/day, respectively.
  • Common adverse events included non-specific central nervous system side effects; no major cardiac effects were reported.

Conclusions:

  • Ezogabine/retigabine is an effective adjunctive treatment for adult partial-onset seizures.
  • RTG demonstrates a favorable efficacy profile with manageable side effects.
  • RTG has received regulatory approval in Europe and the USA for this indication.